Nevirapine Cristers (Nevirapine)

Nevirapine binds to a specific hydrophobic pocket on the HIV‑1 reverse transcriptase enzyme, distinct from the nucleoside binding site. This binding causes a conformational change that blocks the enzyme’s activity, preventing the conversion of viral RNA into DNA and thereby inhibiting viral replication.

The dosing regimen for nevirapine is individualized by the prescribing clinician based on the patient’s age, weight, CD4 count and treatment history. Standard regimens typically involve an initial lead‑in period followed by a maintenance dose, but exact amounts must be determined by a qualified healthcare professional.

Nevirapine can be used during pregnancy when the benefits outweigh potential risks, especially for preventing mother‑to‑child transmission of HIV. However, initiation in women with high CD4 counts (>250 cells/µL) is associated with an increased risk of hepatic toxicity. Breastfeeding decisions should follow local guidelines and consider infant exposure.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nevirapine belongs to the NNRTI class, similar to efavirenz and rilpivirine. Compared with efavirenz, nevirapine has a lower incidence of central nervous system side effects but a higher risk of skin rashes and hepatic toxicity. Choice of agent depends on patient tolerance, resistance profile and co‑medication considerations.

Nevirapine Cristers should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct sunlight, and avoid storing them in bathrooms or near heat sources to maintain product stability.

Nevirapine is administered orally as a tablet. It may be taken with or without food, but consistent intake with respect to meals helps maintain stable plasma levels. Patients should swallow the tablet whole and follow the prescriber’s schedule for lead‑in and maintenance dosing.

The most serious adverse events include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, and potentially life‑threatening hepatic injury. Early signs such as rash, fever, jaundice, or unexplained fatigue require immediate medical evaluation and possible discontinuation of therapy.

Nevirapine is contraindicated in patients with known hypersensitivity to the drug, those with moderate to severe hepatic impairment, and individuals with a history of severe cutaneous adverse reactions to NNRTIs. Caution is also advised for patients with high baseline CD4 counts, especially women, due to increased risk of liver toxicity.